Merck & Co., Inc. Restructuring Reserve, Period Expense (Deprecated 2012-01-31)
Merck & Co., Inc. (MRK) reported Restructuring Reserve, Period Expense (Deprecated 2012-01-31) of $116.00 million for the 3-month period ending 2011-03-31, per its 10-Q filed 2011-05-09.
Discontinued › Notes › Restructuring and Related Activities
us-gaap:RestructuringReservePeriodExpense · last filed 2011-05-09
- Merck & Co., Inc. restructuring reserve, period expense (deprecated 2012-01-31) for the quarter ending 2011-03-31 was $116.00M, a 66.67% decline year-over-year.
- Merck & Co., Inc. restructuring reserve, period expense (deprecated 2012-01-31) for the quarter ending 2010-03-31 was $348.00M.
- Merck & Co., Inc. restructuring reserve, period expense (deprecated 2012-01-31) for fiscal 2010 was $1.97B, a 1.86% increase from fiscal 2009.
- Merck & Co., Inc. restructuring reserve, period expense (deprecated 2012-01-31) for fiscal 2009 was $1.94B, a 50.70% increase from fiscal 2008.
- Merck & Co., Inc. restructuring reserve, period expense (deprecated 2012-01-31) for fiscal 2008 was $1.28B.
| Period end | Restructuring Reserve, Period Expense (Deprecated 2012-01-31) 3 month | Restructuring Reserve, Period Expense (Deprecated 2012-01-31) 12 month |
|---|---|---|
| 2011-03-31 | $116.00M 10-Q · filed 2011-05-09 | |
| 2010-12-31 | $1.97B 10-K · filed 2011-02-28 | |
| 2010-03-31 | $348.00M 10-Q · filed 2011-05-09 | |
| 2009-12-31 | $1.94B 10-K · filed 2011-02-28 | |
| 2008-12-31 | $1.28B 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |